HLX55
/ Fosun Pharma, Shanghai Henlius Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 01, 2020
Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status
(clinicaltrials.gov)
- P1; N=98; Recruiting; Sponsor: Henlix, Inc; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • KRAS • MET
January 22, 2020
Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status
(clinicaltrials.gov)
- P1; N=98; Not yet recruiting; Sponsor: Henlix, Inc; Initiation date: Nov 2019 ➔ Apr 2020
Clinical • Trial initiation date • KRAS • MET
1 to 2
Of
2
Go to page
1